Abbott Settles 2,000 NEC Claims for $670M, Shifts Legal Strategy

Abbott's $670 million settlement of approximately 2,000 necrotizing enterocolitis (NEC) claims tied to its preterm infant formulas closes one chapter of a sprawling litigation, but the learned intermediary doctrine rulings embedded in the case record now carry direct implications for how QA and regulatory affairs teams structure labeling and safety communication for high-risk specialty products.

The settlement resolves the Gill case, in which a St. Louis jury awarded $495 million in July 2024, and an additional tranche of roughly 2,000 individual claims. Abbott had appealed the Gill verdict to the Missouri Court of Appeals in December 2024; the appeal was denied. Rather than pursuing further appeal or paying approximately $600 million representing the judgment plus accrued interest, Abbott negotiated an aggregate resolution of approximately $670 million across both the Gill matter and the additional claims. The agreements carry no admission of liability.

The settlement lands against a backdrop of favorable judicial outcomes for preterm formula manufacturers. In July 2026, the U.S. Court of Appeals for the Seventh Circuit affirmed a pretrial judgment for Abbott in the first federal Multidistrict Litigation bellwether case. In June 2026, the Illinois Appellate Court reversed a $60 million verdict against Mead Johnson, finding the trial court failed to properly apply the learned intermediary doctrine, a ruling with direct relevance to labeling defense strategy across a substantial number of pending cases. A Florida state court reached a similar dismissal in March 2026 on the same doctrine.

For regulatory affairs leads, the Illinois and Florida rulings are the more operationally significant data points. The learned intermediary doctrine governs a manufacturer's duty to warn and, when correctly applied, routes that duty through the prescribing clinician rather than directly to the patient or family. Labeling that clearly delineates the clinical population, contraindications, and risk context, consistent with 21 CFR Part 201 requirements, strengthens the evidentiary foundation for that defense. QA teams managing post-market surveillance documentation for specialty or high-risk products should review whether their current safety communication records would support the same argument under scrutiny.

Abbott notes that the FDA, NIH, CDC, American Academy of Pediatrics, and the NEC Society have each affirmed that preterm infant formulas are safe and necessary, and that no reliable scientific evidence links them to NEC causation. Approximately 1,700 lawsuits involving claims on behalf of roughly 12,700 individual infants remain pending in federal and state courts; Abbott states it is actively working to identify and eliminate duplicative or unsupported claims across jurisdictions.

The pace at which courts apply the learned intermediary doctrine in the remaining 1,700 lawsuits will serve as a measurable indicator of whether the June 2026 Illinois appellate ruling reshapes the litigation's trajectory at scale.

Source: Abbott MediaRoom via PRNewswire, 20 August 2026.